News stories about Neos Therapeutics (NASDAQ:NEOS) have been trending somewhat positive on Monday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neos Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.2210062064442 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of research analysts recently weighed in on the stock. ValuEngine lowered shares of Neos Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 2nd. Zacks Investment Research lowered shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price objective on shares of Neos Therapeutics in a research note on Wednesday, August 8th. Finally, Wells Fargo & Co reduced their price objective on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $13.33.
Neos Therapeutics stock traded up $0.17 during mid-day trading on Monday, reaching $5.52. The company’s stock had a trading volume of 11,640 shares, compared to its average volume of 243,607. Neos Therapeutics has a 12-month low of $5.13 and a 12-month high of $13.15. The firm has a market capitalization of $158.76 million, a price-to-earnings ratio of -2.07 and a beta of -0.37. The company has a current ratio of 1.07, a quick ratio of 0.84 and a debt-to-equity ratio of -2.36.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
See Also: How to Use the New Google Finance Tool
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.